SCHEMBL1795166

SCHEMBL1795166

COC(=O)c1nc(C)cc(-c2cc(F)cc(F)c2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.42
NPC1 O15118 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
KMT2A Q03164 2/20 0.38
GAA P10253 1/20 0.38
ALDH1A1 P00352 3/20 0.38
ADORA1 P30542 1/20 0.38
PLA2G2A P14555 1/20 0.38
KDM4E B2RXH2 3/20 0.38
HPGD P15428 2/20 0.37
DHODH Q02127 1/20 0.37
MEN1 O00255 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CGAS Q8N884 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1799136 0.82 KMO (0.46) ADORA2ASMN1; SMN2KMT2AALDH1A1ADORA1
SCHEMBL9461176 0.77 KDM4E (0.53) SMN1; SMN2KMT2AALDH1A1KDM4EHPGD
SCHEMBL1796672 0.77 SMN1; SMN2 (0.40) ADORA2ANPC1CASP3RAB9ASMN1; SMN2
SCHEMBL15534617 0.77 ADORA3 (0.50) NPC1CASP3RAB9ASMN1; SMN2SENP8
SCHEMBL1793676 0.73 MAPT (0.51) NPC1RAB9ASMN1; SMN2KMT2AHPGD
SCHEMBL1797145 0.72 ADORA2A (0.46) ADORA2AKMT2AGAAADORA1
SCHEMBL1795369 0.72 GRM5 (0.41) ADORA2ANPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL1795702 0.72 GRM5 (0.51) KMT2AMEN1GRM5
SCHEMBL1794913 0.71 GRM5 (0.51) ADORA2AGRM5
SCHEMBL1796422 0.71 ADORA2A (0.45) ADORA2ASMN1; SMN2KMT2AALDH1A1ADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951824-B2 4-aryl-pyridine-2-carboxyamide derivatives HOFFMAN-LA ROCHE INC. (US) 2011-05-31 US disclosed
EP-1987003-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-11-05 EP disclosed
WO-2007093542-A1 PYRIDINE-2-CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-23 WO disclosed
US-20070197553-A1 4-Aryl-pyridine-2-carboxyamide derivatives HOFFMANN-LA ROCHE INC. 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197553-A1 4-Aryl-pyridine-2-carboxyamide derivatives GRM2, GRM1, GRM3 ADORA2A 200/4885NPC1 2924/4885CASP3 4040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.